Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of X-396(Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase Ⅱ, Open-Label, Single Arm, Multicenter Study

NCT03753685 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03753685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03753685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of X-396(Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase Ⅱ, Open-Label, Single Arm, Multicenter Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 12, 2019
Completion date
June 30, 2026
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, nonsmall cell lung cancer